Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Asker Healthcare, Audiocast, Q1'26

By Inderes5/6/2026, 8:00 AM
Asker Healthcare

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Johan Falk
00:01 - 04:06

Hi everyone, this is Johan Falk and welcome to the Q1 report. As we said in the headline, a strong start to the year. And that's how we feel. So we have a good Q1 behind us now. The growth of the adjusted EBITDA was 21%. And we all know that 4% headwind could have taken us to 25% in total if it wasn't for the FX effect, but 21% we're proud of as well. Of course, of that, 8% was organic. Very importantly, if we look at the margin, 9.8% is coming closer to the 10% short-to-mid-term targets, representing a 70-basis-point increase. So that is also a signal of good efficiency and purchasing power within the group, which we are utilizing effectively. If you just look on the highlight side here, we have net sales of 4.5 billion this quarter, up 13%, with 5% organic top-line growth, which is faster than the market; Adjusted EBITDA was 442 million, up 21%, as I mentioned, and 8% organic. So a bit faster bottom line growth than top line growth, which we like, and showing the efficiency and scale that we now can see of the group. We have an adjusted EBITA margin strengthened by 70 basis points, up to 9.8%. You might remember that we had 10% in Q4, but that is our strongest quarter of the year. So we have a steady uptick towards the 10% margin target. Robust cash flow this quarter thanks to strong earnings growth and from the two new acquisitions signed during the quarter. So that's also good to see that we are continuing our high pace of M&A with our own cash flow. But that is staying steady with leverage below 2.5, as we have communicated before, and looking on a rolling 12-month basis, we have delivered on our most important financial targets. I promised to deliver adjusted EBITDA over 15% per year, which we have for many years, and now it's 18% for the last 12 months; our R/RK (EBITA/NWC) is a very important efficiency measure for our operations. So 68%, a level we are proud of maintaining. I mentioned the adjusted EBITDA margin, 9.7% on a rolling 12-month basis. Hopefully, we will break through the ceiling of 10% on the yearly basis as well. In not too long a future. 2.15 is the Net Debt/EBITDA leverage ratio. Tom will come back to that a little bit later in the report, but the overall message is that we're keeping that steady, as we now are doing. Tom will come back to that a little bit later in the report, but the overall message is that we're keeping that steady and as we now are. I've been here many years, as many of you know. 14, I think it is. And we have been fortunate to deliver quarter-by-quarter organic growth as well as M&A. And this is another quarter which we add to the series. The yellow line here is representing the 15% growth. And I'm happy to stay above that, which we have no reason to believe we can't do going forward. Now, into some details with Tom.

Thomas Moss
04:06 - 14:39

Great. Thanks, Johan. I will add some numbers just to support the messages that Johan has given there. So overall, the group financial performance was very solid in the quarter. And pleasing for us to see good organic growth across the group. And I think one of the things that is most satisfying is that this growth is genuinely broad based across the regions, across the companies, across the countries, coming both from well-established businesses within the group, but also the recent M&A, driving both growth and margin improvement. We look at some of the numbers. Johan mentioned them already. Net sales in Q1 up 13%. 5% of that organic. With the FX headwind that we have been struggling a bit with in recent quarters. Adjusted EBITA up 21% in Q1, 8% of that organic. And also with the FX headwind affecting the EBITA side of things as well, but margin up to 9.8%, as Johan mentioned, continuing to move in the right direction. If we go one level further down and look in a little bit more detail at the business areas, starting with Business Area North, performing well, with good organic growth across the region. Important to note that the large defence and preparedness sales that we have talked about during 2025 are now out of the comps, so it's good to see a clean quarter that shows how this region is doing without those comps confusing the picture. And we see adjusted EBITDA growth of 5%, with 4% of that organic, and net sales growth of 7%, with organic growth also at 7% in the quarter. A brief mention of the new Distribution Centre that we've talked about also in the past down in the southwest of Sweden, progressing nicely. We're starting to do some tests in the facility which have delivered good results. And as a reminder, we will be ramping up that activity through the course of this year. There will be some additional double manning costs and some additional inventory coming in towards the end of 2026 and 2027. We will be fully operational in the early part of 2027 and the full personnel benefits coming through in the second half of 2027. Business Area. West. Strong growth in the region. And pleasing to see that we are really getting some benefits from some of the scale effects in the region. So we see adjusted EBITDA growing 32%, of which 15% of that was organic. And we see net sales growing 12%, with organic growth contributing 5% to the net sales, quite a large negative FX effect in region West. And the margin, as I mentioned before, moving nicely in the right direction up to 9.5% in the quarter. And, to reiterate the message for the group as a whole and all other regions, we see good organic growth from both established businesses and acquired units. With a particular note on Region West, where we see strong performance from our home care operations, which continue to find additional growth opportunities and are really starting to see some nice scale benefits from those operations, which is good to see. Turning to the third business area. Central. Also strong sales and EBITDA growth across the region. Net sales up 26%, 13% organic, and Adjusted EBITDA up 47% in the quarter. Organic growth contributing on the net sales side, 3%. And again, I repeat the message, but really a broad-based contribution to the growth across the companies, across the countries within the region. And as we've talked about before, we continue to focus on margin enhancing activities in the region. Just to look at the range, look at the portfolio, take out some of the less attractive products and segments from the range here. Turning now briefly to our R/RK EBITA over net working capital. We talked about this many times. I always talk about it. It's a key internal metric for us, making sure that we're really focusing hard on our capital efficiency and capital utilization. And as we've also talked about many times before, an important source of the cash that we use to fund the M&A engine. So, good to see that that's still performing well across the group in the quarter. The overall picture is really good, solid, robust cash flows. The overall picture is really good, with solid, robust cash flows. And hence that feeds into good visibility around our M&A planning as well. And hence, that feeds into good visibility around our M&A planning as well. I'll say a few more words about that in a second. Cash flow from operating activities 419 million SEK in the quarter. Naturally driven by the strong top and bottom line that I've talked about on the previous pages, but also the continued work we do around working capital efficiency and squeezing cash out there. I should note that the 109 million that we saw in Q1 2025 was an abnormally low figure. We had numerous costs, if you remember, associated with the IPO and other related activities. So although cash flow is good and solid, and we're happy with 419, perhaps the growth is a little bit flattered by the low figure we had in the comparable period. Regarding CAPEX, I briefly mentioned the Distribution Centre a few pages ago. We have approximately 100 million SEK remaining to be paid out for that DC over the next 9 to 12 months, but as we've said, the development of that DC is progressing nicely. Looking ahead to future cash flows, particularly in Q2, we've had a few questions about this. I've discussed this with analysts and investors. So just to be super transparent on this, we do have a relatively large earnout cash outflow coming in Q2 450 million SEK approximately. So those, as a reminder, are for deals that were done, M&A deals that were done back in 2022 to some extent, 2023. Those businesses have developed well. They have reached the end of their earnout period at the end of 2025. And then we pay the Earnouts after we've got the annual reports signed off and audited for those businesses, which is why we have the big cash outflow in Q2 450 million. As I say, we have the dividend of 149 million SEK. Our first dividend, which will flow out during May. I want to emphasize that these non-regular cash outflows that we see coming up in Q2 are well modeled. They're well understood. They're fully built into our thinking, our leverage planning, our debt planning. And of course that then leads into our capacity to do M&A. And perhaps I also add a further note when you look forward to the Earnouts in 2027, i.e. For deals that we did in 2023 and to some extent 2024, whose earnout period comes to an end at the end of 2026, we expect that cash out amount to be around 130 million SEK. I think it's interesting just to contrast that with the relatively larger amount that we're going to be paying out now in Q2 2026. And I think that's an indication, not that those businesses have performed less well, but more that we have evolved our earnout model as we have gone forward through the development of our second engine. And then one final page from me just taking the cash flow and the leverage discussion one step further. We have a stable leverage well below our target of 2.5, giving us good capacity for those continued acquisitions that are that key fundamental second engine. That's a part of our business. A few numbers on this page. So I tried to take them steadily so we don't get confused. The Net Debt to EBITDA, according to our current definition and our current 2.5x target, comes in at 2.15 during the quarter. But for the two deals that we've completed in the quarter, Van Heek and GHC, we haven't yet fully paid out all of the cash for those acquisitions. The reason for that is we're actually waiting for the final annual reports, the audited annual reports. We like to receive that before we complete all of the cash outflow. But clearly those are part of those deals. Those are cash amounts that are associated with completed deals. To be completely open, transparent, and clear, we've added those back. And when that amount is added back, you see that actually 2.25 is the leverage in the quarter. And I think that's the more relevant figure to look at. And you can see on the right-hand side of this picture, the chart, our leverage is extremely stable. We manage it in a good way and we're conscious to keep it at that stable level. I add one further footnote. Again, simply because I've discussed this so much with analysts and investors, there is an alternative way of looking at the leverage ratio. And actually, this way is equivalent to our bank's leverage covenant definition. And that would be to include all of the earn outs and outstanding payments for the next 12 months in the debt side of the calculation, but at the same time to also include the 12 month pro forma EBITDA from acquisitions that we've done, which I also think is very reasonable. These are businesses that are now part of the Asker group, and their cash-generating capacity is part of the group. So it's only reasonable to include that as well. And if you were to use this alternative leverage calculation, you would come to a figure of 2.36. Just to reinforce again, that is not our current definition, but it's another way of looking at it. And I think what it does when you see that is it just reinforces the point that the strong and stable cash flows that this business generates enable us to manage leverage, have good insight, and deliver on our M&A agenda going forwards. With that, I pass back to Johan.

Johan Falk
14:39 - 18:49

Thank you, Tom, and good bridge to M&A. We use our strong cash flow to welcome new companies to the group. As I mentioned many times before, we're improving the pipeline and being a market leader in Europe now in medical supplies, devices and equipment across 19 countries. We're seen as the natural leader, and we see that family businesses, entrepreneurial-led businesses want to join the group because they see that they will perform even better, and they are among friends and helping healthcare improve in Europe. So if anything, every quarter that I've presented this, we have a stronger and stronger pipeline and we are selective. We pick the best ones out of it. Last year, it was around 15 deals we've done, and we had a pipeline of close to 90 deals we could have done. So that gives an indication of how we work with this, and this quarter is no exception. We have welcomed GHC/MPF and also Van Heek Medical, adding some 650 million in annual sales. We have also done the acquisition of RMS. . Medical Devices that was signed in Q1 was completed on April 1st. And I think all of these deals now and going forward will contribute positively to our EBITDA margin. So if anything, we are cherry-picking the ones that are above 10% EBITDA margin to start with. We have also, on top of the scale and positive synergy effect, we also have a positive mix effect, helping us to improve the margin. If we do a deep dive, as I usually do, into one of the acquisitions, to give you a flavour of how we help healthcare, nurses, doctors, and patients across Europe, we have GHC MPF, which is two interlinked medical supplies companies within the homecare segment where we are strong. And this time it was in Germany. So we're helping them with incontinence and urology products. So that's a strong need and an attractive niche. They're adding roughly 300 million in revenue, and they are a team of 140 employees with expertise in these fields, which really supports them. The home care patient in Germany. And that also has a positive EBITDA margin effect. All right. Coming to summarize this quarter, as you can hear, we're happy and proud of having a good start to 2026. Being on this fantastic journey of consolidating the MedTech market in Europe, helping the healthcare system to improve. We have seen that we are continuing to grow faster than the market. This quarter was 5% top line. We're getting the scale effects out of our operations. So 8% adjusted EBITDA growth on the bottom line. And the acquisitions are coming in and will hopefully continue to do so during the current year, the following year, and the year after, with a strong cash flow, a good pipeline, and a very good team centrally as well as locally, helping us find the best entrepreneurial opportunities. So I think that will pretty much summarize the quarter, and our visibility is good, as you know, medical supplies, devices, and equipment. Regardless of the tough times around the world, we are in constant need of these products. Even if the financial climate is tough and the war is going on, we need these to take care of our loved ones. And that's what we see. Also, the type of customer relationship we have with long customer contracts. We have good visibility. And for that reason, we feel that we have good progress today, but also good visibility for the rest of the year, both in M&A and organic growth. So thank you very much. I think we go from here to Q&A.

Operator
18:50 - 19:07

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the Q. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Eric Cassel from Danske Bank. Please go ahead.

Eric Cassel
19:09 - 19:47

Hi. Good morning everyone. First, I wanted to discuss North's organic growth a bit more. Is it possible to sort of split out the different parts of North? Specifically, if we can talk a bit about Innomedicus, how's that doing? And then I also wanted to discuss the distribution rights of the orthopedic contract that you bought in the Baltics. Is it possible that that's somehow Q1 weighted, and if so, how meaningful is that to the reported organic growth? We are seeing this in Q1.

Johan Falk
19:48 - 20:49

I'll just start and hand over to you, Tom. More specifically, I think in general, we have a very broad base of growth in all regions, starting with the whole group across the 19 countries. So it's not that we have a concentrated growth and profit from some areas. And that goes for the North as well. And specifically for Onemed, where we've been working for many, many years. And we see that the trust from our customers in Sweden, comprising 290 municipalities, 20 regions, and roughly 100 private companies, is well spread across those. And we have a strong tender team winning tenders and contracts. And that can go a little bit up and down. But in general, if you look back ten years, that has been an increase in trust from customers and an increase in growth. So One Med is stronger than ever, I would say, in the underlying business. Maybe you want to add something, Tom.

Thomas Moss
20:50 - 21:19

No, I support that. I think the growth, as we've said through the presentation, is genuinely broad based. It's broad-based in North. It's broad based across the regions. Eric, just to take your specific question about the distribution rights in Benelux, it's small numbers. We're talking low tens of millions of SEK of revenue and very low single-digit millions of SEK in EBITA contribution.

Eric Cassel
21:22 - 21:33

Okay. But it's just possible to frame if, say, OneMed was near the 7% or if there are other parts, say something in Norway that stood out with, say, double digits instead.

Thomas Moss
21:34 - 21:55

No, as Johan said, we are going to be a bit reluctant to go into individual companies or countries in too much detail. But no, the simple answer to your question is that there is no spike in any individual company or any individual product. The growth is genuinely broad-based across the regions and the company.

Eric Cassel
21:56 - 22:28

Okay. Good to hear. Then I just wanted to ask a bit on the acquisition margins. I tried to do some math on Van Heek and the GHC contributions that you had now in this quarter. And to me, that sort of implies that those companies had 18% EBITDA margins. Now in Q1, you obviously haven't disclosed the underlying margins for it, but would you say that like 18% is some sort of normalized level or is that contribution going to fall for the full year?

Thomas Moss
22:28 - 23:06

Got it. I think, yeah, that 18% sounds a little bit punchy. I would say, for commercial reasons, we don't want to be too specific on the margins of the deals that we buy. But you can read a little bit into the way we communicate the margins. So when we say it's margin accretive, we mean it's a little bit above the kind of 10% average of the group. If we start talking about very accretive, then you could perhaps guess that we're above 15% margin. And these deals are accretive rather than very accretive, I would say.

Eric Cassel
23:08 - 23:46

Okay. Got it, got it. Then I remember normally that there tends to be more pricing adjustments in Q1 compared to the other quarters in the year. I guess that's primarily for North and MedTech. But I just wanted to ask now, what sort of pricing tailwinds do you expect to see now for 26? If you've had some adjustment outcomes now in Q1, and also how you would compare that to what you're expecting to see for input cost increases? Now that there seems to be a bit higher overall cost inflation going on.

Johan Falk
23:47 - 25:27

Yeah. I'm sorry. It seems like we're answering the same thing on all the questions, but given the extreme broad base we have in our 60 companies, 19 countries, 2000 suppliers and thousands and thousands of products and also customers, I would say it's like a white noise. It's a little bit of everything across the year. So there is no specific spike. And then if you go down to a specific country, to a specific contract, of course you can see such trends. But I think the message for Asker as a whole is, I usually give an example. It's like a floating bit of cork on the water. When it goes up and down, we follow it in a good way. If anything is problematic and disturbs the picture, such as during a pandemic or other disruptions, we usually come out on the positive side by being a little bit quicker to act. Being a little bit more forward-leaning. So when the world is changing, we usually have a slight positive effect. But that should not be taken into any dramatic picture. And now when we have the current situation, we haven't so far seen any problems with this. Of course, our products are so broadly based and some of them are oil-based, so we are keeping a close eye on it. We have been very quick this time as well to secure supply, making sure that we have good logistics so we don't get disturbed. But so far we haven't seen it. And also on the price side, we see if anything, it could be a slight uptick, but you should see it as a normal business.

Eric Cassel
25:29 - 25:40

Okay. So nothing has really changed on the volume, price, and mix. We expect to see organic growth this year compared to previous years. Essentially what you're saying.

Johan Falk
25:40 - 25:41

Yes.

Eric Cassel
25:43 - 25:46

Okay, perfect. Thank you very much. I'll jump back in queue.

Johan Falk
25:46 - 25:47

Thank you.

Operator
25:50 - 25:53

The next question comes from Jakub Lemke from Seb. Please go ahead.

Jakub Lemke
25:56 - 26:16

Yes. Hi and good morning. My first question is on the West home care business. I'm wondering if you're securing new clients here now, should we then assume that you have secured more recurring revenues and that we should expect this higher EBITA growth to remain here for a few quarters?

Thomas Moss
26:18 - 26:36

And just to be super clear, Jakub, I guess when you say clients, you mean patients in their home, because the funding system in home care in the Netherlands is primarily driven by the big insurance companies. It's so we're talking about patient numbers or did I misinterpret your question?

Jakub Lemke
26:37 - 26:39

Yes, I meant patients.

Thomas Moss
26:39 - 27:58

Yeah. Yeah. So, so I think, um, you know, when you see double digit growth in North, there is um, sorry in West. I think if I was building a model, I wouldn't build in plus 15% growth in West in perpetuity. I think that would be a little bit on the ambitious side, but it is fair to say that we are doing well in West. We are growing that business organically. And as I mentioned, the scale benefits that we got, we had a little bit of discussion around this in Q4 because we've had a bit of a warehouse reorganization, for example, in West and finding those benefits. We have had for a long time in the group, a large business called Bosman that has continuously and consistently done extremely well. We bought another large business called Medeva 3 or 4 years ago. That's really running at full steam now as well. So the combination of those, the scale that we're getting from those and the extremely good relationships we have with patients and the insurance companies means that there's no reason not to believe that we will continue to deliver good results from West. But I'm certainly not going to sit here and tell you that you should model 15% organic growth in West going forward. That, I think, would be a little bit extreme.

Jakub Lemke
28:01 - 28:13

That sounds fair. Then on North, I'm wondering what's the reason that the organic growth is higher for top line than on EBITDA, indicating a lack of scaling.

Thomas Moss
28:13 - 29:05

Yeah, I can take that one. I think this one is much more driven by normal fluctuations. If I can put it that way. I certainly wouldn't read too much into the 0.3% drop in margin quarter on quarter; the actual amount of money involved to swing the margin by that amount is relatively small. And as Johan and I are keen to emphasize, you really should look at these things on a rolling 12-month basis. And what we see is that North is a region that delivers above 13% consistently. We're super happy with that. But there is no one factor that means that there is a mathematical, technical, small margin drop in the numerical figures presented for North this quarter. It merely is just the normal fluctuations within the business.

Jakub Lemke
29:09 - 29:17

Okay. And then a question on the seasonality in North. Is it fair to assume that Q2 normally is a bit stronger than Q1?

Thomas Moss
29:17 - 29:41

Correct. Yeah. We typically see in North that Q2 is a strong quarter. Sometimes it's affected a little bit where Easter falls, whether that falls in Q1 or Q2. But typically Q2 is a stronger quarter in North. There's a little bit of preparation pre-summer that goes on in many of the countries in North. And then Q3 tends to be a weaker quarter in North. Yeah.

Jakub Lemke
29:44 - 30:05

And then finally, just how we should read your comments about the leverage and cash outflow in Q2. Does that mean that we should expect maybe a bit more of a quiet period now for M&A and then sort of getting back to full throttle in the second half, or do you think that you can close anything here also more short term?

Thomas Moss
30:05 - 31:32

I can take that with a slightly longer-term perspective. Jacob, you know, we've set to grow EBITDA by 15%, as we've said. We hope and anticipate that organically we will deliver five, six, seven, or eight percent. And then on top of that, we've said we want to add 10 to 12% EBITA on an annual basis from M&A to enable us to reach that 15% and above. We are very confident that we will be able to add M&A contributing 10 to 12% of our EBITDA through the whole of 2026. As a little side note, you can do a bit of a back of the envelope calculation yourself. The deals that we've already done get us close to 50%. If you include MBS, 40%, if you just look at Van Heek and GHC. So in terms of our trajectory, the amount of M&A we want to do, the pace at which we want to do it, we are absolutely on track. Whether that means there will be ten deals in June or not. In some ways, we are confident that we will get there full year. So, we have a good pipeline. We have plenty of deals lined up, depending on more local technical circumstances and exactly when they will be signed. But the overall perspective is the pipeline is good. We're proceeding according to plan. We're adding M&A as we want to, and we have very good visibility because of the stability of the cash flows.

Jakub Lemke
31:35 - 31:40

Okay. Sounds fair. Maybe just a short final one. If you can give an update on the Kirstine Hardam acquisition.

Johan Falk
31:41 - 32:44

Yes, I can do that. We have a very good relationship with the owner of Hardham. That's actually not the private player this time. It's more of a big American company where we have a good collaboration in many aspects. When it comes to the specific Hardham case, it's going through an authority process, which takes a lot of time. And usually, we don't have these long, long periods. So right now, we have not closed it. And we'll see where that will end up. If anything, we have such a long pipeline, so there will be alternatives if Hardham does not happen. We have five ready to take that position right away because today our limit is the cash flow. We have. We have a long lineup of companies that want to come in, so Hardham. It has been an exceptionally long authority process, which we usually don't have. So, it's not closed, and we will see what happens, and we will inform you as soon as we have the information.

Jakub Lemke
32:47 - 32:49

When do you expect to get a decision?

Johan Falk
32:50 - 33:14

We cannot say that, but hopefully in the near future it's been dragging on for longer than we had expected. I mean, we're down close to 70 deals. This is an outlier from that. So this is not usually how it plays out. So hopefully within the near future, I would say we know how to do it. And we have a good dialogue with the owner to manage the process.

Jakub Lemke
33:16 - 33:18

Okay. Understood. That's all for me. Thank you.

Johan Falk
33:18 - 33:19

Thank you.

Operator
33:20 - 33:32

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Albin Nordmark from SB1 Markets. Please go ahead.

Albin Nordmark
33:35 - 33:59

Yes. Thanks. Albin here. So, starting off with the gross margin, it's quite solid here, up year over year. So can you split that between the product, customer mix, input cost dynamics, FX, or operating leverage? And also, what should we expect here going forward? This is a normal level. So to say.

Thomas Moss
33:59 - 34:25

That's an easy question you throw out there. I think I go back a little bit to what Johan and I have said: the mix in the organization is now so broad – 19 countries, 60 companies, everything from large, expensive pieces of medical equipment to everyday consumables and supplies. So it's almost meaningless to try and break it down to group level.

Albin Nordmark
34:27 - 34:31

But if we try with only FX, then how much is FX driven?

Thomas Moss
34:33 - 34:33

How much.

Albin Nordmark
34:33 - 34:33

Is it?

Thomas Moss
34:34 - 36:01

FX driven? I think typically we are buying and selling products in local currencies. So we source them in the local currency and then sell them in the local currency, the -4% FX impact that you see at a group level is driven by the translation effects, the weakness of the euro versus the SEK. I.

I would just say in terms of gross margin, gross margins are dependent on the business model. So typically, larger pieces of equipment have slightly higher gross margins, but also bigger costs lower down the PNL, and more consumables products have lower gross margins, but less cost lower down the PNL. So there is a significant mix impact on that, especially if you look back over 5 or 6 years of how this group has changed and developed. But I would also say that as we become bigger and stronger, we are able to use that to have more robust conversations with our OEMs. You know, we're not going to get squeezed down the line. So I think for us, predicting exactly how gross margins develop is not super helpful in terms of how we look going forward. It depends a little bit on how the mix of the group develops.

Albin Nordmark
36:01 - 36:06

No input prices in US dollars then?

Thomas Moss
36:06 - 36:40

No, I think, a little bit as John mentioned, we tend to move as the market moves. So we do not get squeezed in the middle of this chain. We're never going to be in a situation where an OEM increases the price by 10%, and we're not able to pass that through to our customer. What will happen is we will hold back that price increase versus the OEM and in some cases pass it through to the customer. So, the position that we're in now, the strength that we have, the relationships that we have mean that we are well-positioned. We are not going to be the victim of that squeeze if that were to occur.

Albin Nordmark
36:42 - 36:55

All right. That's clear. And then Earnouts, you mentioned 130,000,000 in 2027 and 415,000,000 in Q2 total. You have above 1 billion. So, do you have any more in H2?

Thomas Moss
36:55 - 37:26

No, sorry. Perhaps I should have been clear about that. So there are future earnouts that will be paid in 2028 and 2029, which make up the total. So there's around 200 million per year in 2028 and 2029. But there are no other earn out payments that will be made beyond the 450,000,000 in 2026. And as I say, the total forecast of earn-out payments for full year 2027 at the moment stands at around 130 million SEK. Sorry, I should have made that clear as I went through it earlier.

Albin Nordmark
37:28 - 37:49

Yes, that's clear now. Thanks. And then mentioning the scale of benefits both in the report and now in the call. So how should we think here, especially in the West? So how much is utilized, so to say, and how is it possible to quantify the benefits of scale ahead in 26.

Thomas Moss
37:49 - 38:57

I would again, I would take a sort of a broader perspective on it. If you go back 5 or 6 years, the group has grown its margin from 6.5% to the 9.5% we have today. So, we have consistently added around half a percentage point of margin on an annual basis. And that half a percentage point of margin has come very roughly, half from the M&A we've done and the mix enrichment derived from it. And the other half a percentage point, or a quarter of a percentage point if you can put it that way, has come from organic operating efficiencies. And of course, that will vary a little bit over time depending on exactly what activities we do. We will get larger increases in margin where there is more headroom in West and Central. Probably the margin will increase less rapidly in North. But big picture over time. I see no reason why we will not continue to improve margins at the rate that we have done historically.

Albin Nordmark
38:59 - 39:13

Okay. Thanks. That's clear as well. And then one last on the tax rate. It's quite lumpy now, 23% down from 29% but still up quarter on quarter. So how should we think about the tax rate.

Thomas Moss
39:13 - 40:14

Yes, lumpy is the word. I think last year with IPO and changes of financing structure and many things going on did confuse the picture a little bit. We are a low 20s tax business. You know, that is what we are fundamentally at our operating core and over time, paid tax and P&L tax should normalize and come together at the same rate. So if I was building a model going forwards, I would put in 22-23% as penal tax and paid tax. So I think what you see in Q1, the 23% is the more normal, clean rate of tax. The historical lumpiness has had all sorts of strange things in it. But going forward, we are a 22-23% tax business. We are not doing aggressive tax planning. We are not doing complicated things with our structures to try to avoid paying taxes. So so that's what I put into the model.

Albin Nordmark
40:16 - 40:18

Okay, great. Thanks to all from me.

Johan Falk
40:18 - 40:19

Thank you.

Operator
40:20 - 40:26

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Johan Falk
40:27 - 40:32

All right. So we're coming to an end. Thank you very much for listening in. And see you next quarter.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…